Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 17/20 | 0.56 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.56 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 9/20 | 0.54 |
| ▸ | MAPK12 | P53778 | 9/20 | 0.54 |
| ▸ | MAPK11 | Q15759 | 9/20 | 0.54 |
| ▸ | RAF1 | P04049 | 7/20 | 0.54 |
| ▸ | BRAF | P15056 | 1/20 | 0.54 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.54 |
| ▸ | GCGR | P47871 | 1/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21574554 | 1.00 | ALOX5 (0.62) | ALOX5MAPK14CSNK1DCSNK1EMAPK13 | |
| SCHEMBL21068026 | 0.97 | ALOX5 (0.58) | ALOX5MAPK14CSNK1DCSNK1EMAPK13 | |
| SCHEMBL15606600 | 0.89 | MAPK14 (0.71) | MAPK14CSNK1DCSNK1EMAPK13MAPK12 | |
| SCHEMBL4565197 | 0.88 | MAPK14 (0.72) | ALOX5MAPK14CSNK1DCSNK1EMAPK13 | |
| SCHEMBL6447875 | 0.87 | MAPK13 (0.72) | ALOX5MAPK14CSNK1DMAPK13MAPK12 | |
| SCHEMBL4552055 | 0.86 | MAPK14 (0.76) | ALOX5MAPK14CSNK1DCSNK1EMAPK13 | |
| SCHEMBL6926311 | 0.85 | TEK (0.65) | ALOX5MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL7146991 | 0.82 | MAPK14 (0.80) | ALOX5MAPK14CSNK1DCSNK1EMAPK13 | |
| SCHEMBL6605306 | 0.81 | MAPK14 (0.68) | ALOX5MAPK14CSNK1DCSNK1EMAPK13 | |
| SCHEMBL6449407 | 0.81 | MAPK14 (0.77) | ALOX5MAPK14CSNK1DCSNK1EMAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203155-A1 | Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections | AXXIMA PHARMACEUTICAL AG. (DE) | 2005-09-15 | — | — | US | claimed |
| EP-1532118-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2005-05-25 | — | — | EP | claimed |
| WO-2004005264-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | AXXIMA PHARMACEUTICALS AG (DE) | 2004-01-15 | — | — | WO | claimed |
| US-20030082519-A1 | Cellular kinases involved in Cytomegalovirus infection and their inhibition | AXXIMA PHARMACEUTICALS AG (DE) | 2003-05-01 | — | — | US | claimed |
| EP-1261334-A1 | IRRIGATION SOLUTION CONTAINING MAPK INHIBITORS AND THEIR USE FOR TREATING PAIN AND INFLAMMATION | Omeros Corporation (US) | 2002-12-04 | — | — | EP | claimed |
| US-20020028798-A1 | Irrigation solution and method for inhibition of pain and inflammation | OMEROS MEDICAL SYSTEMS | 2002-03-07 | — | — | US | claimed |
| WO-2000023072-A1 | IRRIGATION SOLUTION CONTAINING MAPK INHIBITORS AND THEIR USE FOR TREATING PAIN AND INFLAMMATION | OMEROS MEDICAL SYSTEMS, INC. (US) | 2000-04-27 | — | — | WO | claimed |
| US-20240000821-A1 | CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER | UNIV JOHNS HOPKINS (US) | 2024-01-04 | — | — | US | disclosed |
| US-20220062252-A1 | CYCLOOXYGENASE INHIBITOR AND CALCIUM CHANNEL ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN UROLOGICAL PROCEDURES | OMEROS CORP (US) | 2022-03-03 | — | — | US | disclosed |
| US-20210290605-A1 | CYCLOOXYGENASE INHIBITOR AND CALCIUM CHANNEL ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN UROLOGICAL PROCEDURES | OMEROS CORP (US) | 2021-09-23 | — | — | US | disclosed |
| US-20200276166-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | UNIV CALIFORNIA (US) | 2020-09-03 | — | — | US | disclosed |
| US-10668049-B2 | Methods of treating cognitive decline with transforming growth factor beta inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200078387-A1 | CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER | THE JOHNS HOPKINS UNIVERSITY | 2020-03-12 | — | — | US | disclosed |
| US-6849409-B2 | Cellular kinases involved in Cytomegalovirus infection and their inhibition | AXXIMA PHARMACEUTICALS AG (DE) | 2005-02-01 | — | — | US | disclosed |
| WO-2004005264-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | AXXIMA PHARMACEUTICALS AG (DE) | 2004-01-15 | — | — | WO | disclosed |
| US-20030096807-A1 | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation | OMEROS CORPORATION | 2003-05-22 | — | — | US | disclosed |
| US-20030087962-A1 | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation | OMEROS CORPORATION | 2003-05-08 | — | — | US | disclosed |
| EP-1261334-A1 | IRRIGATION SOLUTION CONTAINING MAPK INHIBITORS AND THEIR USE FOR TREATING PAIN AND INFLAMMATION | Omeros Corporation (US) | 2002-12-04 | — | — | EP | disclosed |
| US-20020028798-A1 | Irrigation solution and method for inhibition of pain and inflammation | OMEROS MEDICAL SYSTEMS | 2002-03-07 | — | — | US | disclosed |
| WO-2000023072-A1 | IRRIGATION SOLUTION CONTAINING MAPK INHIBITORS AND THEIR USE FOR TREATING PAIN AND INFLAMMATION | OMEROS MEDICAL SYSTEMS, INC. (US) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082519-A1 | Cellular kinases involved in Cytomegalovirus infection and their inhibition | CDC42BPG, CDC42BPB, CDC7 | ALOX5 4798/4885MAPK14 126/4885CSNK1D 514/4885 |
| US-20050203155-A1 | Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections | CSNK1G1, CSNK1E, CSNK1D | ALOX5 4787/4885MAPK14 662/4885CSNK1D 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.